Boston Scientific Total Liabilities & Equity increased by 2.3% to $43.67B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 10.9%, from $39.40B to $43.67B. Over 5 years (FY 2020 to FY 2025), Total Liabilities & Equity shows an upward trend with a 7.3% CAGR.
An increase typically reflects overall balance sheet growth or expansion of the company's asset base, while a decrease may indicate divestitures or debt repayment.
This represents the sum of all claims against a company's assets, combining obligations to external creditors and the re...
This is a standard accounting identity used across all industries to verify that assets equal the sum of liabilities and equity.
total_liabilities_and_equity| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $31.17B | $31.88B | $32.23B | $32.34B | $32.19B | $31.95B | $32.47B | $32.89B | $33.60B | $34.04B | $35.14B | $36.67B | $37.11B | $38.08B | $39.40B | $40.14B | $41.56B | $42.71B | $43.67B |
| QoQ Change | — | +2.3% | +1.1% | +0.3% | -0.5% | -0.8% | +1.6% | +1.3% | +2.2% | +1.3% | +3.2% | +4.4% | +1.2% | +2.6% | +3.5% | +1.9% | +3.5% | +2.8% | +2.3% |
| YoY Change | — | — | — | — | +3.3% | +0.2% | +0.7% | +1.7% | +4.4% | +6.6% | +8.2% | +11.5% | +10.4% | +11.9% | +12.1% | +9.5% | +12.0% | +12.2% | +10.9% |